Amylyx Pharmaceuticals, Inc. (AMLX) Insider Trading Activity
NASDAQ$4.84
Market Cap
$431.44M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
185 of 877
Rank in Industry
104 of 506
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
| $337M | ||
| $259M | ||
| $79M | ||
| $76M | ||
| $60M | ||
| $57M |
AMLX Insider Trading Activity
AMLX Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $464,763 | 4 | 17 |
Sells | $677,713 | 19 | 83 |
Related Transactions
| MILNE GEORGE M JR | director | 1 | $219,800 | 0 | $0 | $219,800 |
| Firestone Karen | director | 1 | $106,590 | 0 | $0 | $106,590 |
| FRATES JAMES M | Chief Financial Officer | 1 | $101,368 | 1 | $37,806 | $63,562 |
| Zeiher Bernhardt G | director | 1 | $37,005 | 0 | $0 | $37,005 |
| Mazzariello Gina | Chief Legal Officer | 0 | $0 | 5 | $90,801 | $-90,801 |
| Bedrosian Camille L | Chief Medical Officer | 0 | $0 | 3 | $109,649 | $-109,649 |
| Klee Justin B. | Co-Chief Executive Officer | 0 | $0 | 5 | $219,672 | $-219,672 |
| Cohen Joshua B | Co-Chief Executive Officer | 0 | $0 | 5 | $219,785 | $-219,785 |
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Amylyx Pharmaceuticals, Inc.
Over the last 12 months, insiders at Amylyx Pharmaceuticals, Inc. have bought $464,763 and sold $677,713 worth of Amylyx Pharmaceuticals, Inc. stock.
On average, over the past 5 years, insiders at Amylyx Pharmaceuticals, Inc. have bought $12.52M and sold $12.7M worth of stock each year.
Highest buying activity among insiders over the last 12 months: MILNE GEORGE M JR (director) — $219,800. Firestone Karen (director) — $106,590. FRATES JAMES M (Chief Financial Officer) — $101,368.
The last purchase of 10,000 shares for transaction amount of $37,005 was made by Zeiher Bernhardt G (director) on 2025‑03‑20.
List of Insider Buy and Sell Transactions, Amylyx Pharmaceuticals, Inc.
| 2025-03-31 | Sale | Cohen Joshua B | Co-Chief Executive Officer | 21,490 0.0237% | $3.47 | $74,482 | +23.59% | |
| 2025-03-31 | Sale | Klee Justin B. | Co-Chief Executive Officer | 21,490 0.0237% | $3.46 | $74,454 | +23.59% | |
| 2025-03-31 | Sale | FRATES JAMES M | Chief Financial Officer | 10,896 0.0121% | $3.47 | $37,806 | +23.59% | |
| 2025-03-31 | Sale | Bedrosian Camille L | Chief Medical Officer | 12,425 0.0137% | $3.47 | $43,082 | +23.59% | |
| 2025-03-31 | Sale | Mazzariello Gina | Chief Legal Officer | 9,192 0.0102% | $3.48 | $31,954 | +23.59% | |
| 2025-03-20 | Zeiher Bernhardt G | director | 10,000 0.0112% | $3.70 | $37,005 | +9.92% | ||
| 2025-03-03 | Sale | Cohen Joshua B | Co-Chief Executive Officer | 4,595 0.0056% | $3.17 | $14,549 | +27.33% | |
| 2025-03-03 | Sale | Klee Justin B. | Co-Chief Executive Officer | 4,595 0.0056% | $3.15 | $14,483 | +27.33% | |
| 2025-03-03 | Sale | Mazzariello Gina | Chief Legal Officer | 1,611 0.0019% | $3.12 | $5,022 | +27.33% | |
| 2025-02-24 | Sale | Mazzariello Gina | Chief Legal Officer | 4,169 0.0046% | $3.15 | $13,145 | +26.00% | |
| 2025-02-03 | Sale | Cohen Joshua B | Co-Chief Executive Officer | 11,851 0.0131% | $3.47 | $41,108 | +9.06% | |
| 2025-02-03 | Sale | Klee Justin B. | Co-Chief Executive Officer | 11,855 0.0131% | $3.47 | $41,104 | +9.06% | |
| 2025-02-03 | Sale | Mazzariello Gina | Chief Legal Officer | 3,678 0.0041% | $3.49 | $12,839 | +9.06% | |
| 2025-01-06 | Sale | Cohen Joshua B | Co-Chief Executive Officer | 7,471 0.0112% | $4.05 | $30,232 | -6.89% | |
| 2025-01-06 | Sale | Klee Justin B. | Co-Chief Executive Officer | 7,471 0.0112% | $4.04 | $30,202 | -6.89% | |
| 2024-12-02 | Sale | Bedrosian Camille L | Chief Medical Officer | 5,421 0.0078% | $5.54 | $30,007 | -32.07% | |
| 2024-09-30 | Sale | Cohen Joshua B | Co-Chief Executive Officer | 18,589 0.0156% | $3.20 | $59,414 | +19.44% | |
| 2024-09-30 | Sale | Klee Justin B. | Co-Chief Executive Officer | 18,589 0.0156% | $3.20 | $59,429 | +19.44% | |
| 2024-09-30 | Sale | Bedrosian Camille L | Chief Medical Officer | 11,442 0.0096% | $3.20 | $36,559 | +19.44% | |
| 2024-09-30 | Sale | Mazzariello Gina | Chief Legal Officer | 8,709 0.0073% | $3.20 | $27,840 | +19.44% |
Total: 69
*Gray background shows transactions not older than one year
Insider Historical Profitability
32.16%
| Klee Justin B. | Co-Chief Executive Officer | 3355276 3.764% | $16.24M | 0 | 9 | |
| Cohen Joshua B | Co-Chief Executive Officer | 3355280 3.764% | $16.24M | 0 | 9 | |
| MILNE GEORGE M JR | director | 858571 0.9632% | $4.16M | 2 | 1 | +36.36% |
| FRATES JAMES M | Chief Financial Officer | 290988 0.3264% | $1.41M | 1 | 6 | |
| Bedrosian Camille L | Chief Medical Officer | 194375 0.2181% | $940,775.00 | 0 | 3 | |
| Mazzariello Gina | Chief Legal Officer | 187969 0.2109% | $909,769.96 | 0 | 10 | |
| Firestone Karen | director | 55000 0.0617% | $266,200.00 | 3 | 0 | |
| Zeiher Bernhardt G | director | 10000 0.0112% | $48,400.00 | 1 | 0 | |
| Morningside Venture Investments Ltd | 10 percent owner | 6997302 7.8497% | $33.87M | 1 | 10 | +23.76% |
| ALS Invest 1 B.V. | 5937577 6.6609% | $28.74M | 0 | 1 | ||
| VIKING GLOBAL INVESTORS LP | 2300000 2.5802% | $11.13M | 1 | 0 | +23.76% | |
| Olinger Margaret | Chief Commercial Officer | 214355 0.2405% | $1.04M | 1 | 1 | +36.36% |
| Yeramian Patrick D | Chief Medical Officer | 205605 0.2307% | $995,128.20 | 0 | 5 | |
| Cheng Isaac | director | 6578 0.0074% | $31,837.52 | 1 | 0 | +36.36% |
| Quimi Daphne | director | 5000 0.0056% | $24,200.00 | 2 | 0 | |
| FONTEYNE PAUL R. | director | 3947 0.0044% | $19,103.48 | 1 | 0 | +36.36% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$587,109,125 | 90 | 3.17% | $428.01M | |
$24,384,691 | 42 | -30.27% | $452.58M | |
$16,271,606 | 27 | 24.11% | $431.19M | |
$6,280,187 | 19 | 6.80% | $431.46M | |
$111,056,143 | 19 | -7.49% | $421.82M | |
$3,287,638 | 15 | -0.23% | $507.66M | |
$152,858,569 | 14 | -4.66% | $412.73M | |
$18,455,830 | 13 | 24.59% | $460.01M | |
$133,809,976 | 13 | 31.29% | $473.71M | |
$3,073,199 | 10 | 16.77% | $401.48M | |
$135,543,039 | 9 | -5.28% | $401.02M | |
$38,624,786 | 9 | 1.26% | $442.61M | |
Amylyx Pharmaceuticals, Inc. (AMLX) | $49,529,960 | 6 | 32.16% | $431.44M |
$3,200,000 | 5 | -11.36% | $481.76M | |
$18,704,399 | 5 | -20.93% | $393.59M | |
$960,000 | 2 | 15.91% | $464.16M | |
$504,640 | 1 | 16.84% | $401.82M | |
$3,850,000 | 1 | -51.32% | $445.93M | |
$3,250,000 | 1 | -44.91% | $425.4M |
AMLX Institutional Investors: Active Positions
| Increased Positions | 71 | +59.66% | 16M | +37.1% |
| Decreased Positions | 49 | -41.18% | 9M | -20.28% |
| New Positions | 30 | New | 4M | New |
| Sold Out Positions | 17 | Sold Out | 4M | Sold Out |
| Total Postitions | 141 | +18.49% | 52M | +16.82% |
AMLX Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Perceptive Advisors Llc | $36,040.00 | 7.61% | 6.77M | +5M | +218.7% | 2024-12-31 |
| Tcg Crossover Management, Llc | $24,705.00 | 5.22% | 4.64M | 0 | 0% | 2024-12-31 |
| Vanguard Group Inc | $14,324.00 | 3.03% | 2.69M | -397,156 | -12.85% | 2024-12-31 |
| Bank Of America Corp /De/ | $12,908.00 | 2.73% | 2.43M | +2M | +165.89% | 2024-12-31 |
| Blackrock, Inc. | $12,701.00 | 2.68% | 2.39M | +108,475 | +4.76% | 2025-03-31 |
| Almitas Capital Llc | $10,812.00 | 2.28% | 2.03M | +43,807 | +2.2% | 2024-12-31 |
| Citadel Advisors Llc | $10,484.00 | 2.21% | 1.97M | +71,144 | +3.75% | 2024-12-31 |
| 683 Capital Management, Llc | $10,268.00 | 2.17% | 1.93M | -70,000 | -3.5% | 2024-12-31 |
| Goldman Sachs Group Inc | $9,895.00 | 2.09% | 1.86M | +246,033 | +15.24% | 2024-12-31 |
| Boxer Capital Management, Llc | $9,310.00 | 1.97% | 1.75M | +2M | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Price to Earnings
Price/Earnings to Growth
Price to Sales
Price to Book
Price/Free Cash Flow
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.